In today’s recent session, 0.5 million shares of the AnaptysBio Inc (NASDAQ:ANAB) have been traded, and its beta is -0.05. Most recently the company’s share price was $18.84, and it changed around $1.76 or 10.30% from the last close, which brings the market valuation of the company to $577.76M. ANAB at last check was trading at a discount to its 52-week high of $41.31, offering almost -119.27% off that amount. The share price’s 52-week low was $12.21, which indicates that the recent value has risen by an impressive 35.19% since then. We note from AnaptysBio Inc’s average daily trading volume that its 10-day average is 0.82 million shares, with the 3-month average coming to 951.19K.
AnaptysBio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended ANAB as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. AnaptysBio Inc is expected to report earnings per share of -1.46 for the current quarter.
AnaptysBio Inc (NASDAQ:ANAB) trade information
Instantly ANAB has been showing a green trend so far today with a performance of 10.30% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 20.71 on recent trading dayincreased the stock’s daily price by 9.03%. The company’s shares are currently up 42.30% year-to-date, but still up 14.11% over the last five days. On the other hand, AnaptysBio Inc (NASDAQ:ANAB) is 1.34% up in the 30-day period. We can see from the shorts that 9.03 million shares have been sold at a short interest cover period of 6.91 day(s).
The consensus price target as assigned by Wall Street analysts is $40, which translates to bulls needing to increase their stock price by 52.9% from its current value. Analyst projections state that ANAB is forecast to be at a low of $19 and a high of $80.
AnaptysBio Inc (ANAB) estimates and forecasts
The year-over-year growth rate is expected to be -54.00%, down from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 13.58M in revenue for the current quarter. 11 analysts expect AnaptysBio Inc to make 8.58M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 7.18M and 10.97M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 89.19%. Forecasts for the next quarter put sales growth at -21.81%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -7.30%. AnaptysBio Inc earnings are expected to increase by -5.25% in 2025, but the outlook is negative -4.00% per year for the next five years.
AnaptysBio Inc (NASDAQ:ANAB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.41% of AnaptysBio Inc shares, and 121.92% of them are in the hands of institutional investors. The stock currently has a share float of 127.54%. AnaptysBio Inc stock is held by 193.0 institutions, with ECOR1 CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 27.4931% of the shares, which is about 7.52 million shares worth $188.48 million.
FMR LLC, with 10.4936% or 2.87 million shares worth $71.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
SPDR(R) S&P(R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 31, 2025. The former held 754.85 shares worth $14.54 million, making up 2.46% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 668.95 shares worth around $12.88 million, which represents about 2.18% of the total shares outstanding.
